Lister Ta

431 total citations
11 papers, 346 citations indexed

About

Lister Ta is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Lister Ta has authored 11 papers receiving a total of 346 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Genetics, 5 papers in Pathology and Forensic Medicine and 5 papers in Hematology. Recurrent topics in Lister Ta's work include Chronic Lymphocytic Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Acute Myeloid Leukemia Research (4 papers). Lister Ta is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Lymphoma Diagnosis and Treatment (5 papers) and Acute Myeloid Leukemia Research (4 papers). Lister Ta collaborates with scholars based in United Kingdom and United States. Lister Ta's co-authors include BD Young, Van de Ven Wj, Mark Bower, J. Amess, Gerald A. Evans, Pauline Parry, D. Crowther, Dean Nižetić, Susheela Dhut and Robert E. Kearney and has published in prestigious journals such as Blood, PubMed and UCL Discovery (University College London).

In The Last Decade

Lister Ta

11 papers receiving 324 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lister Ta United Kingdom 9 181 143 92 81 70 11 346
C. Fonatsch Germany 8 213 1.2× 207 1.4× 97 1.1× 64 0.8× 74 1.1× 17 401
Quoc‐Hung Le France 12 240 1.3× 153 1.1× 129 1.4× 73 0.9× 128 1.8× 32 443
Parvaneh Vossough Iran 13 97 0.5× 162 1.1× 148 1.6× 76 0.9× 89 1.3× 29 436
Ester Rosenthal Israel 9 128 0.7× 97 0.7× 69 0.8× 37 0.5× 38 0.5× 13 324
Rika Kanezaki Japan 11 163 0.9× 198 1.4× 78 0.8× 47 0.6× 69 1.0× 19 387
K Ohishi Japan 7 134 0.7× 163 1.1× 46 0.5× 83 1.0× 24 0.3× 11 386
A Jacobs United Kingdom 7 240 1.3× 158 1.1× 97 1.1× 120 1.5× 37 0.5× 12 421
M Deminatti France 12 376 2.1× 170 1.2× 224 2.4× 26 0.3× 99 1.4× 45 534
A Hermans Netherlands 7 144 0.8× 160 1.1× 77 0.8× 59 0.7× 66 0.9× 12 337
Colin Grace United Kingdom 13 252 1.4× 158 1.1× 188 2.0× 43 0.5× 55 0.8× 20 463

Countries citing papers authored by Lister Ta

Since Specialization
Citations

This map shows the geographic impact of Lister Ta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lister Ta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lister Ta more than expected).

Fields of papers citing papers by Lister Ta

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lister Ta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lister Ta. The network helps show where Lister Ta may publish in the future.

Co-authorship network of co-authors of Lister Ta

This figure shows the co-authorship network connecting the top 25 collaborators of Lister Ta. A scholar is included among the top collaborators of Lister Ta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lister Ta. Lister Ta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Wj, Van de Ven, et al.. (1996). A new member of the proprotein convertase gene family (LPC) is located at a chromosome translocation breakpoint in lymphomas.. PubMed. 56(3). 448–51. 88 indexed citations
2.
Kearney, Robert E., Dean Nižetić, Susheela Dhut, et al.. (1994). Molecular cloning of a novel 11q23 breakpoint associated with non-Hodgkin's lymphoma.. PubMed. 9(3). 893–8. 12 indexed citations
3.
Bower, Mark, Pauline Parry, J. Amess, et al.. (1994). Prevalence and clinical correlations of MLL gene rearrangements in AML- M4/5. Blood. 84(11). 3776–3780. 69 indexed citations
4.
Radford, John, et al.. (1990). VAPEC B: a weekly chemotherapy for high grade non-Hodgkin's lymphoma. Early results of a collaborative trial at two centres.. UCL Discovery (University College London). 1 indexed citations
5.
Ta, Lister & D. Crowther. (1990). Staging for Hodgkin's disease.. PubMed. 17(6). 696–703. 16 indexed citations
6.
Ta, Lister, Renato Bassan, Walter M. Gregory, et al.. (1987). Conventional dose cytosine arabinoside in combination chemotherapy for acute myelogenous leukemia.. PubMed. 14(2 Suppl 1). 53–4. 4 indexed citations
7.
Ta, Lister, et al.. (1985). The use of high-dose cytosine arabinoside for non-Hodgkin's lymphoma.. PubMed. 12(2 Suppl 3). 223–6. 11 indexed citations
8.
Ta, Lister, et al.. (1982). Posttreatment laparotomy as a guide to management in patients with Hodgkin's disease.. PubMed. 66(4). 759–65. 13 indexed citations
9.
Hg, Prentice, et al.. (1979). Limited activity of ICRF-159 in advanced acute leukemia.. PubMed. 63(1). 127–9. 9 indexed citations
10.
Ta, Lister, et al.. (1978). Plasma cell leukemia (PCL): A report on 15 patients. Blood. 52(4). 839–845. 70 indexed citations
11.
Ta, Lister, et al.. (1972). The treatment of acute myelogenous leukemia in adults.. PubMed. 13(1). 172–83. 53 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026